Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.
Read More »How Does Empagliflozin Reduce Cardiovascular Mortality In Type 2 Patients, Including Those With PAD?
Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies
Patients are not seeing the expected results because of medication adherence.
Read More »Why Are We Waiting To Treat Diabetes Until A1c Reaches 6.5%?
Getting type 2 diabetes at an early age increases risk for all diabetes complications, including death.
Read More »SGLT-2 Inhibitors Vs DPP-4 Inhibitors Vs. GLP1’s For Type 2 Diabetes
How best to decide whether to use one or a combination of the new treatments and individualize the treatment for your patients.
Read More »Diabetic Complications and Frostbite
With much of the U.S. in the grip of harsh winter weather as December 2017 comes to a close, we're revisiting a post we originally published in 2013 about how having diabetes or prediabetes can increase the risk of frostbite. The risk was dramatically illustrated by the experience of British explorer Sir Ranulph Fiennes, who had to pull out of a grueling expedition to cross Antarctica due to the effects of frostbite. We wish all our readers a healthy, safe, and warm new year!
Read More »Cholecalciferol Improves Glycemic Control
Study reports Vitamin D supplementation may improve HbA1c and lower cholesterol.
Read More »Common Causes of Death Among Patients with Both Diabetes and ASCVD
Identifying causes of death and related risk factors in patients with type 2 diabetes and cardiovascular disease may help with prevention.
Read More »Greater HbA1c Reduction with DPP4 Inhibitor, AGI Combination
Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.
Read More »Safety and Efficacy of a New Long-Acting Exenatide Formulation: BYDUREON® BCise™
Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.
Read More »Efficacy And Safety When Adding Ertugliflozin to Metformin and Sitagliptin
New SGLT-2 inhibitor can be used as add-on therapy to provide better improvement in HbA1C in patients with type 2 diabetes.
Read More »